Table 1.
Clinicopathologic and histomorphologic features in hepatic steatosis patients
| NAFLD (n = 18) |
AFLD (n = 11) |
Control (n = 38) |
|
|---|---|---|---|
| Clinical Features | |||
| Age, mean (range) years | 23 ± 6.4 (11–36)a | 41 ± 9.5 (23–59)a | 61 ± 12.5 (34–89)a |
| Sex | |||
| male | 15 (83%) | 9 (82%) | 11 (29%) |
| female | 3 (17%) | 2 (18%) | 27 (71%) |
| BMI | |||
| underweight | 0 | 1 (9%) | 2 (5%) |
| normal | 3 (17%) | 6 (55%) | 13 (34%) |
| overweight | 0 | 2 (18%) | 15 (39%) |
| obese | 15 (83%) | 2 (18%) | 8 (21%) |
| Liver Biochemistry | |||
| AST/ALT ratio | |||
| ≤2 | 14 (78%) | 6 (55%) | – |
| > 2 | 4 (22%) | 5 (45%) | – |
| AST, median (mean, range) U/L | 79 (67, 11~ 192) | 67 (105, 21~ 152) | 22 (35, 12~ 249) |
| ALT, median (mean, range) U/L | 84 (124, 11~ 384) | 44 (35, 12~ 204) | 17 (31, 7~ 252) |
| TB, median (mean, range) mg/dL | 0.8 (0.9, 0.5~ 12.4) | 14 (9, 0.7~ 19.8) | 0.7 (0.8, 0.3~ 3.5) |
| Histomorphological Features | |||
| Steatosis | None | ||
| 5–33% | 4 (22%) | 2 (18%) | |
| > 33–66% | 5 (28%) | 5 (45%) | |
| > 66% | 9 (50%) | 4 (36%) | |
| Lobular inflammation (inflammatory foci/200× field) | None | ||
| < 2 | 16 (89%) | 6 (55%) | |
| 2–4 | 2 (11%) | 3 (27%) | |
| > 4 | 0 | 2 (18%) | |
| Ballooning degeneration | None | ||
| none | 9 (50%) | 1 (9%) | |
| few | 8 (44%) | 5 (45%) | |
| many | 1 (6%) | 5 (45%) | |
| Fibrosis | None | ||
| none | 6 (33%) | 1 (9%) | |
| perisinusoidal or peripota1 | 11 (61%) | 1 (9%) | |
| Perisinusoidal & potal/periportal | 1 (6%) | 1 (9%) | |
| bridging fibrosis | 0 | 3 (27%) | |
| cirrhosis | 0 | 5 (45%) | |
NAFLD non-alcoholic fatty liver disease
AFLD alcoholic fatty liver disease
Control, 16 cases of biliary cyst and 22 cases of hepatolithiasis
amean ± standard deviation
AST aspartate transaminase
ALT alanine transaminase
TB total bilirubin